832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM)

Dimitriou, F., Hassel, J. C., Orloff, M., Hughes, I., Kapiteijn, E., Mehmi, I., Montazeri, K., Johnson, D. B., Grover, P., Gerard, C. L., Simeone, E., Gaudy Marqueste, C., Cheng, P., Long, G. V., Carvajal, R. D., & Dummer, R. (2022). 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM). Annals of Oncology, 33, S929. https://doi.org/10.1016/j.annonc.2022.07.958
Authors:
Florentia Dimitriou
J.C. Hassel
Marlana Orloff
I. Hughes
Ellen Kapiteijn
Inderjit Mehmi
K. Montazeri
D.B. Johnson
P. Grover
Camille L. Gérard
Ester Simeone
C. Gaudy Marqueste
Phil F. Cheng
Georgina V. Long
Richard D. Carvajal
R. Dummer
Affiliated Authors:
I. Hughes
Richard D. Carvajal
Columbia Affiliation:
Subjects:
Immunobiology of Dendritic Cells (OpenAlex Topic)
Ocular Cancer Research and Treatment (OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1016/j.annonc.2022.07.958
DOI:
10.1016/j.annonc.2022.07.958
Journal:
Annals of Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: